These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 24043136)
1. DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft. Zheng MF; Shen SY; Huang WD Cancer Chemother Pharmacol; 2013 Nov; 72(5):1031-41. PubMed ID: 24043136 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295 [TBL] [Abstract][Full Text] [Related]
3. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. Han JY; Hong EK; Lee SY; Yoon SM; Lee DH; Lee JS J Clin Pathol; 2005 Jun; 58(6):650-4. PubMed ID: 15917420 [TBL] [Abstract][Full Text] [Related]
4. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Fujimoto-Ouchi K; Tanaka Y; Tominaga T Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360 [TBL] [Abstract][Full Text] [Related]
5. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma. Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242 [TBL] [Abstract][Full Text] [Related]
6. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074 [TBL] [Abstract][Full Text] [Related]
8. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762 [TBL] [Abstract][Full Text] [Related]
10. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Aprile G; Mazzer M; Moroso S; Puglisi F Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Sawada N; Kondoh K; Mori K Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932 [TBL] [Abstract][Full Text] [Related]
14. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
15. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692 [TBL] [Abstract][Full Text] [Related]
16. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer. Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378 [TBL] [Abstract][Full Text] [Related]
17. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. Zhou J; Tang ZY; Fan J; Wu ZQ; Ji Y; Xiao YS; Shi YH; Li XM; Sun QM; Liu YK; Ye SL Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6030-7. PubMed ID: 14676129 [TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Shi H; Jiang J; Ji J; Shi M; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J Cancer Lett; 2014 Jul; 349(2):128-35. PubMed ID: 24746899 [TBL] [Abstract][Full Text] [Related]
19. Moving forward with capecitabine: a glimpse of the future. Biganzoli L; Martin M; Twelves C Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317 [TBL] [Abstract][Full Text] [Related]
20. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Saif MW; Black G; Johnson M; Russo S; Diasio R Cancer Chemother Pharmacol; 2006 Dec; 58(6):771-5. PubMed ID: 16552574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]